Articles with public access mandates - Yi Lisa HwaLearn more
Not available anywhere: 8
A modern primer on light chain amyloidosis in 592 patients with mass spectrometry–verified typing
E Muchtar, MA Gertz, RA Kyle, MQ Lacy, D Dingli, N Leung, FK Buadi, ...
Mayo Clinic Proceedings 94 (3), 472-483, 2019
Mandates: US National Institutes of Health
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ...
Leukemia 32 (10), 2240-2249, 2018
Mandates: US National Institutes of Health
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains
S Sidana, N Tandon, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, ...
Leukemia 32 (3), 729-735, 2018
Mandates: US National Institutes of Health
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
A Lakshman, S Paul, SV Rajkumar, RP Ketterling, PT Greipp, ...
Leukemia 32 (8), 1811-1815, 2018
Mandates: US National Institutes of Health
Tumor markers for early detection of ovarian cancer
J Ren, H Cai, Y Li, X Zhang, Z Liu, JS Wang, YL Hwa, Y Zhang, Y Yang, ...
Expert Review of Molecular Diagnostics 10 (6), 787-798, 2010
Mandates: US National Institutes of Health
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
E Muchtar, MA Gertz, TV Kourelis, S Sidana, RS Go, MQ Lacy, FK Buadi, ...
Leukemia 34 (4), 1135-1143, 2020
Mandates: US National Institutes of Health
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
S Sidana, N Tandon, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, ...
Leukemia 33 (3), 730-738, 2019
Mandates: US National Institutes of Health
MM-315: Impact of Stratification of Levels of Serum Lactate Dehydrogenase (LDH) at Diagnosis on Overall Survival (OS) in Newly Diagnosed Multiple Myeloma (NDMM)
LA Evans, SK Kumar, A Dispenzieri, FK Buadi, D Dingli, MQ Lacy, ...
Clinical Lymphoma Myeloma and Leukemia 21, S435, 2021
Mandates: US National Institutes of Health
Available somewhere: 81
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ...
Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017
Mandates: US National Institutes of Health
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ...
Blood cancer journal 8 (6), 59, 2018
Mandates: US National Institutes of Health
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016
P Kapoor, SM Ansell, R Fonseca, A Chanan-Khan, RA Kyle, SK Kumar, ...
JAMA oncology 3 (9), 1257-1265, 2017
Mandates: US National Institutes of Health
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
WI Gonsalves, FK Buadi, S Ailawadhi, PL Bergsagel, AA Chanan Khan, ...
Bone marrow transplantation 54 (3), 353-367, 2019
Mandates: US National Institutes of Health
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
N Majithia, SV Rajkumar, MQ Lacy, FK Buadi, A Dispenzieri, MA Gertz, ...
Leukemia 30 (11), 2208-2213, 2016
Mandates: US National Institutes of Health
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
N Abdallah, SV Rajkumar, P Greipp, P Kapoor, MA Gertz, A Dispenzieri, ...
Blood cancer journal 10 (8), 82, 2020
Mandates: US National Institutes of Health
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia
S Sidana, SV Rajkumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, ...
American journal of hematology 92 (7), 668-673, 2017
Mandates: US National Institutes of Health
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
M Binder, SV Rajkumar, RP Ketterling, PT Greipp, A Dispenzieri, MQ Lacy, ...
Blood cancer journal 7 (9), e600-e600, 2017
Mandates: US National Institutes of Health
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
WI Gonsalves, SV Rajkumar, A Dispenzieri, D Dingli, MM Timm, ...
Leukemia 31 (1), 130-135, 2017
Mandates: US National Institutes of Health
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
SK Kumar, B LaPlant, V Roy, CB Reeder, MQ Lacy, MA Gertz, K Laumann, ...
Blood cancer journal 5 (8), e338-e338, 2015
Mandates: US National Institutes of Health
N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
P Milani, S Vincent Rajkumar, G Merlini, S Kumar, MA Gertz, G Palladini, ...
American journal of hematology 91 (11), 1129-1134, 2016
Mandates: US National Institutes of Health, Fondazione Cariplo, Government of Italy
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death
R Warsame, SK Kumar, MA Gertz, MQ Lacy, FK Buadi, SR Hayman, ...
Blood cancer journal 5 (5), e310-e310, 2015
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program